The Free Amino Ion Theory of Cell Stabilization and resultant healing technologies have been in the process of development for more than 30 years and have culminated into the final engineering of hydrogen bonded healing molecules and family of animal and human OTC and ethical pharmaceutical products.
The goal of this research has been to develop a technology platform, resulting in disease specific products that would incorporate the theory of cell stabilization into healthy animal care solutions. Success with ethical animal testing provided the opportunity to test theories and formulations in a variety of applications. At the request of attending physicians, who had heard of the successful trials with farm animals, the cell stabilization formulas were also used to provide relief and comfort to critically ill cancer patients.
According to the Free Amino Ion Theory of Cell Stabilization, when a cell becomes unstable and is unable to restore its stability by process of biosynthesis, the opportunity to mutate can occur. These mutations can lead to a wide variety of problems, some minor, many severe. Over the last three decades, Steven R. Schutt has studied this process. He has invented and developed unique amino acid molecules that release free amino ions which can be integrated into a family of products.
These free amino ions combine with the nucleic acids (within unstable protein nuclei) to achieve the most stable form, and by a process of biosynthesis, causes those formerly unstable proteins to realign. The resulting cellular redifferentiation causes the formerly dysfunctional cells to return to their original preprogrammed function because of already implanted DNA coding. This phenomenon has many positive physiological effects on dysfunctional human and animal cells such as reversing the funcelosa within those dysfunctional cells, thus restoring them to their normal function.
This happens because the cells are differentiated by their original DNA coding, which is still implanted in the errant cells. This process, initiated and achieved by the application of free amino ion releasing products, is thought to be the catalyst in slowing the exponential growth of some cancers as tumorous cells stabilize and are able to return to their normal functioning.
LD 50 studies with 50% H2O solutions and CP powder forms of Triamino™ have shown that the molecule is non-toxic. Pure powder oral ingestion, vapor inhalation, intra-arterial and intravenous administration of Triamino™ in high concentrations all failed to achieve a lethal dose or any visible side effects on mice or rats.
The ramifications of this discovery are enormous. This new molecule will be the cornerstone for a family of health, beauty, and medical products and services.
The Triamino™ molecular structure is fully biocompatible, non-allergenic and does not elicit immune reaction, local or systemic toxicity, or inflammation in animals.